What blood disorders does apotex's ruxolitinib treat?

What blood disorders does Apotex's ruxolitinib treat?

Apotex's ruxolitinib is approved for treating adults with certain blood disorders linked to bone marrow problems. It addresses myelofibrosis, a condition that causes scarring in the bone marrow and reduces blood cell production. It also covers polycythemia vera, a disorder where the bone marrow produces too many red blood cells.

Why does Apotex offer a generic ruxolitinib?

Apotex produces a generic version of ruxolitinib phosphate tablets. The original brand name drug is Jakafi, developed by Incyte Corporation. Apotex entered the market after patent protections expired or were challenged.

When does the ruxolitinib patent expire?

The ruxolitinib main compound patent expires in 2026. Some patents covering formulation and use claims are set to expire later. The company has faced multiple patent challenges from generic manufacturers.

Why does Apotex challenge patents?

Generic companies such as Apotex file abbreviated new drug applications with Paragraph IV certifications. This practice allows them to launch before full patent expiry if they successfully challenge the claims.

Can biosimilars enter before patent expiry?

Ruxolitinib is a small-molecule drug, not a biologic. Therefore, biosimilars are not relevant. Generic small-molecule drugs can enter the market after compound patents expire or through successful patent challenges.

DrugPatentWatch.com